SequelSEC

ImageneBio, Inc. IMA

Biological Products, (No Diagnostic Substances) · CIK 0001835579 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$800.00K
Fiscal year ended 2025-12-31
Operating income
-$48.45M
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

ImageneBio, Inc. (IMA) reported revenue of $800.00K and net income of -$45.35M for the fiscal year ended 2025-12-31. This page shows 6 annual periods of income statement, balance sheet and cash flow figures normalized from ImageneBio, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Biological Products, (No Diagnostic Substances).

Income

ImageneBio, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Revenue$800.00K$3.50M$9.16M$15.62M$30.98M$9.19M
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$48.45M-$37.00M-$75.42M-$70.90M-$34.14M-$44.52M
Net income-$45.35M-$36.57M-$68.17M-$68.76M-$34.12M-$44.26M
Research & development$28.52M$32.11M$59.65M$64.32M$47.11M$44.85M
Weighted-average diluted sharesUnavailableshares 48.26Mshares 41.74Mshares 36.19Mshares 27.98MUnavailable
Pretax income-$45.70M-$36.56M-$68.33M-$68.76MUnavailableUnavailable
Income tax expense-$350.00K$13.00K-$162.00K$0$0Unavailable
Diluted EPS$-9.64$-22.10$-1.63$-1.90$-1.22Unavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$20.73M$8.39M$24.92M$22.20M$18.02M$8.87M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

ImageneBio, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Cash & equivalents$94.53M$12.12M$119.89M$59.92M$232.22M$162.49M
Total assets$152.98M$15.92M$192.09M$172.26M$247.88M$168.40M
Current assets$140.29M$12.47M$178.66M$160.01M$236.52M$165.97M
Total liabilities$19.84M$17.45M$22.34M$25.29M$40.00M$63.47M
Current liabilities$11.23M$17.21M$14.20M$21.50M$27.19M$28.33M
Total equity incl. NCI$133.14M-$160.56M-$126.11M$146.97M$207.88M-$101.05M
Temporary (mezzanine) equityUnavailable$159.04MUnavailableUnavailable$0$205.98M
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$1.44M$5.29M$2.07M$2.09M$2.38M$2.12M

Cash flow

ImageneBio, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Operating cash flow-$47.84M-$21.32M-$79.74M-$74.11M-$60.25M-$37.83M
Capital expendituresUnavailableUnavailable$414.00K$1.43M$1.76M$766.00K
Investing cash flow-$5.81M$11.12M$64.14M-$99.28M-$1.76M$2.92M
Financing cash flow$135.47M$6.91M$75.98M$1.10M$131.74M$116.18M
Net change in cash$82.41M-$3.20MUnavailableUnavailableUnavailableUnavailable
Stock-based compensation$15.39M$0$7.63M$7.52M$5.18M$1.80M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailable$663.00KUnavailableUnavailableUnavailable
Depreciation & amortization$400.00K$1.10MUnavailableUnavailableUnavailableUnavailable

Derived

ImageneBio, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-31
Free cash flowUnavailableUnavailable-$80.16M-$75.54M-$62.01M-$38.59M
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating margin-6056.4%-1057.1%-823.3%-454.0%-110.2%-484.2%
FCF marginUnavailableUnavailable-875.1%-483.7%-200.1%-419.8%
SBC / revenue1923.9%0.0%83.3%48.2%16.7%19.5%
Current ratio12.49x0.72x12.58x7.44x8.70x5.86x
Revenue YoY growth-77.1%-61.8%-41.3%-49.6%237.0%Unavailable
Net margin-5668.6%-1044.8%-744.2%-440.3%-110.1%-481.4%
R&D / revenue3565.6%917.4%651.2%411.8%152.0%487.8%
CapEx / revenueUnavailableUnavailable4.5%9.2%5.7%8.3%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open IMA in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-05View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-03-10View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-07-24View SEC filing
10-Q · Filed 2025-05-08View SEC filing

Companies in the same industry

ABOS ABPO ACOG ADAPY ADMA ADPT AGEN AGTX AIM ALEC ALGS ALLO

Reconciliation checks needing review

1 period on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationreview2023-12-31

Difference 295865000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.